• Main Publications
• Ongoing Research Projects
• Group’s Recognitions
• Clinical Trials Signed in 2018
• Other

​

Main Publications

• Tauriello DVF, Palomo-Ponce S, Stork D, Berenguer-Llergo A, Badia-Ramentol J, Iglesias M, Sevillano M, Ibiza S, Cañellas A, Hernando-Momblona X, Byrom D, Matarín JA, Calon A, Rivas EI, Nebreda AR, Riera A, Attolini CS, Batlle E. TGFβ drives immune evasion in genetically reconstituted colon cancer metastasis. Nature 2018; 554(7693): 538-543. IF 41.577. D1.

• López-Arribillaga E, Rodilla V, Colomer C, Vert A, Shelton A, Cheng JH, Yan B, González-Pérez A, Junttila MR, Iglesias M, Torres F, Albanell J, Villanueva A, Bigas A, Siebel CW, Espinosa L. Manic Fringe deficiency imposes Jagged1 addiction to intestinal tumor cells. Nat Commun 2018; 9(1): 2992. IF 12.353. D1.

• Gallardo F, Bertran J, López-Arribillaga E, González J, Menéndez S, Sánchez I, Colomo L, Iglesias M, Garrido M, Santamaría-Babí LF, Torres F, Pujol RM, Bigas A, Espinosa L. Novel phosphorylated TAK1 species with functional impact on NF-κB and β-catenin signaling in human Cutaneous T-cell lymphoma. Leukemia 2018; 32(10): 2211-2223. IF 10.023. D1.

• Prieto C, López-Millán B, Roca-Ho H, Stam RW, Romero-Moya D, Rodríguez-Baena FJ, Sanjuan-Pla A, Ayllón V, Ramírez M, Bardini M, De Lorenzo P, Valsecchi MG, Stanulla M, Iglesias M, Ballerini P, Carcaboso ÁM, Mora J, Locatelli F, Bertaina A, Padilla L, Rodríguez-Manzaneque JC, Bueno C, Menéndez P. NG2 antigen is involved in leukemia invasiveness and central nervous system infiltration in MLL-rearranged infant B-ALL. Leukemia 2018; 32(3): 633-644. IF 10.023. D1.

• Orozco CA, Martínez-Bosch N, Guerrero PE, Vinaixa J, Dalotto-Moreno T, Iglesias M, Moreno M, Djurec M, Poirier F, Gabius HJ, Fernández-Zapico ME, Hwang RF, Guerra C, Rabinovich GA, Navarro P. Targeting galectin-1 inhibits pancreatic cancer progression by modulating tumor-stroma crosstalk. Proc Natl Acad Sci U S A 2018; 115(16): E3769-E3778. IF 9.504. D1.

• Poves I, Burdío F, Morató O, Iglesias M, Radosevic A, Ilzarbe L, Visa L, Grande L. Comparison of Perioperative Outcomes Between Laparoscopic and Open Approach for Pancreatoduodenectomy: The PADULAP Randomized Controlled Trial. Ann Surg 2018; 268(5): 731-739. IF 9.203. D1.

• Molina-Montes E, Gómez-Rubio P, Márquez M, Rava M, Löhr M, Michalski CW, Molero X, Farré A, Perea J, Greenhalf W, et al. Risk of pancreatic cancer associated with family history of cancer and other medical conditions by accounting for smoking among relatives. Int J Epidemiol 2018; 47(2): 473-483. IF 8.36. D1.

• Lo Re D, Montagner D, Tolan D, Di Sanza C, Iglesias M, Calon A, Giralt E. Increased immune cell infiltration in patient-derived tumor explants treated with Traniplatin: an original Pt(iv) pro-drug based on Cisplatin and Tranilast. Chem Commun 2018; 54(60): 8324-8327. IF 6.29. Q1.

• López-Millán B, Díaz de la Guardia R, Roca-Ho H, Anguita E, Islam ABMMK, Romero-Moya D, Prieto C, Gutiérrez-Agüera F, Bejarano-García JA, Pérez-Simon JA, Costales P, Rovira M, Marín P, Menéndez S, Iglesias M, Fuster JL, Urbano-Ispizua A, Anjos-Afonso F, Bueno C, Menéndez P. IMiDs mobilize acute myeloid leukemia blasts to peripheral blood through downregulation of CXCR4 but fail to potentiate AraC/Idarubicin activity in preclinical models of non del5q/5q- AML. OncoImmunology 2018; 7(9): e1477460. IF 5.503. Q1.

• Gasull M, Pumarega JA, Kiviranta H, Rantakokko P, Raaschou-Nielsen O, Bergdahl IA, Sandanger TM, Goñi F, Cirera L, Donat-Vargas C, et al. Methodological issues in a prospective study on plasma concentrations of persistent organic pollutants and pancreatic cancer risk within the EPIC cohort. Environ Res 2018; 169: 417-433. IF 4.732. D1.

​

​

Ongoing Research Projects

• Impacto de la fragilidad sobre los resultados postoperatorios de la cirugía del cáncer gástrico [TOREGA]

- Financing institution: Asociación Española de Cirujanos

- Period: from 2018 to 2019

- Principal investigator: Pera Román, Manuel Ramón

• Regulación de CDX2 por miRNAs durante el proceso de intestinalización de la metaplasia cardial en un modelo humano de esófago de Barrett

- Financing institution: Fondo de Investigación Sanitaria. ISCIII (PI13/00989)

- Period: from 2014 to 2018

- Principal investigator: Pera Román, Manuel Ramón

• Autoinmunidad, inflamación, y cáncer: el papel mediador de la Ciclina O y su posible aplicación clínica como indicador temprano de transformación tumoral

- Financing institution: Fondo de Investigación Sanitaria. ISCIII (PI13/00864)

- Period: from 2014 to 2018

- Principal investigator: Gil Gómez, Gabriel

 

​

Group’s Recognitions

• Officially recognised as a consolidated research group by the Generalitat de Catalunya: Grup de Recerca en Carcinogènesi Gastroesofàgica i Inestabilitat Genòmica (2017-2020)

- Agència de Gestió d'Ajuts Universitaris i de Recerca (SGR 51)

- Principal investigator: Pera Román, Manuel Ramón

 

​

Clinical Trials Signed in 2018

• A Phase 3, Global Multi-Center, Double-Blind, Randomized, Efficacy Study of IMAB362 Plus mFOLFOX6 Compared with Placebo Plus mFOLFOX6 as First-line Treatment of Subjects with Claudin (CLDN)18.2-Positive, HER2-Negative, Metastatic Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma.

- Register: 8951-CL-0301

- Principal investigator: Visa Turmo, Laura

• Estudio de fase 3, aleatorizado, controlado, abierto y global, comparativo de la eficacia de BGB-A317, un anticuerpo anti-PD-1, frente a quimioterapia como segunda línea de tratamiento en pacientes con carcinoma esofágico epidermoide avanzado no resecable/metastásico.

- Register: BGB-A317-302

- Principal investigator: Visa Turmo, Laura

• Estudio de fase 3, en doble ciego y aleatorizado, de BGB-290 frente a placebo como tratamiento de mantenimiento en pacientes con cáncer gástrico localmente avanzado o metastásico, inoperable, que han respondido a una quimioterapia de primera línea basada en el platino.

- Register: BGB-290-303

- Principal investigator: Visa Turmo, Laura

 

​

Other

• Manuel Pera was appointed Full Professor (Catedrático) in the Universitat Autònoma de Barcelona. October 2018

• Manuel Pera was elected External Examiner at the Trinity College, Dublin, Ireland.

• Manuel Pera was elected Honorary Fellow of the Royal College of Surgeons of Edinburgh. November 2018

• Manuel Pera was elected member of the International Surgical Group (ISG). October 2018

• Manuel Pera was re-elected Director, Executive Committee of the International Society for Diseases of the Esophagus (ISDE). November 2018.

• Extraordinary Doctorate Award 2018 to the student Marta Climent Agustín for her thesis "Resección con pretensión curativa del cáncer gástrico: Influencia de las complicaciones postoperatorias sobre la supervivencia y de la pérdida de peso sobre la calidad de vida".

• Extraordinary Doctorate Award 2018 to the student Yusmeli Salazar-Silva for her thesis "Prótesis de rodilla dolorosa. relación entre la analgesia endógena ineficiente y el dolor postquirúrgico persistente".

 

​